Additionally, exogenous PRDX6 decreases pro-inflammatory cytokine production while promoting anti-inflammatory cytokines in macrophage cultures, helping to mitigate the chronic inflammation that drives MS progression (26). The gene discussed is PRDX6; the disease is myeloid sarcoma.